Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Hematology | Musculoskeletal | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Lovenox (enoxaparin sodium) Injection
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Rhone Poulenc Rorer
Approval Status: Approved February 1998
Treatment Area: prevention of blood clots following hip-replacement surgery
Lovenox (enoxaparin sodium) Injection has been approved for the
extended prevention of deep-vein thrombosis (DVT) following hip
replacement surgery. It was previously approved for use in a
hospital setting, and is the first low-molecular-weight heparin to
be approved for once a day at home use.
In clinical studies, patients discharged for the hospital
without signs of venous thromboembolic disease received either a
three-week regimen of Lovenox, or placebo. Results demonstrated
that the incidence of DVT during the three-week period was
significantly lower in the Lovenox patients, 7% compared to 20% for
Nine percent of patients reported an incidence of injection-site
Mechanism of Action
Lovenox (enoxaparin sodium) is an antithrombotic agent known as
a low-molecular-weight heparin.